Cardiff Scintigraphics, has announced the appointment of OINDP expert John Pritchard as the company’s Chairman of the Board, succeeding David Owen. The news comes soon after Cardiff Scintigraphics, the parent company of inhalation CRO i2c Pharma Services, named Andrew Brown as CEO, succeeding Glyn Taylor.
Pritchard, the 2018 winner of the Charles G. Thiel Award for Outstanding Research and Discovery in Respiratory Drug Delivery, was formerly Chief Technology Officer of the Respiratory Drug Delivery Group at Philips Healthcare and Strategic Technology Director at AstraZenca. He previously held management roles at 3M Drug Delivery Systems and GSK. Pritchard is also Chairman of Nebu-Flow, which is developing nebulizers based on surface acoustic wave (SAW) technology.
Pritchard commented, “I’m looking forward to the challenge of stepping into David’s role at what I think will be very exciting times for the company. The board combines well over 100 years’ experience in the development of respiratory products and so I will have tremendous support from the team.”
Brown said, “John brings a wealth of experience at executive level to CSL/i2c and will play a strong role in the next phase of the company’s expansion and he has the unanimous support of the board.”
Read the Cardiff Scintigraphics press release.
